+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AI-Assisted Drug Discovery Software Market - Global Forecast 2026-2032- Product Image
AI-Assisted Drug Discovery Software Market - Global Forecast 2026-2032- Product Image
Sale

AI-Assisted Drug Discovery Software Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6136377
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The AI-Assisted Drug Discovery Software Market is projected to reach USD 569.69 Million in 2026. It is expected to continue growing at a CAGR of 8.39%, reaching USD 921.74 Million by 2032.

AI-Assisted Drug Discovery Software: Executive Overview

AI-assisted drug discovery software applies machine learning, generative models, knowledge graphs, molecular simulation, and data analytics to activities such as target identification, hit discovery, lead optimization, biomarker analysis, and preclinical planning. Its role is expanding as pharmaceutical, biotechnology, academic, and research organizations seek to integrate heterogeneous biological and chemical data while improving the speed, reproducibility, and prioritization of laboratory work. Adoption depends on scientific validity, data quality, interoperability, regulatory confidence, cybersecurity, and the availability of skilled computational and laboratory personnel.

Scientific Integration Is Reshaping Drug Discovery Workflows

The landscape is shifting from isolated computational experiments toward connected workflows that link literature mining, omics interpretation, structure-based design, molecular generation, property prediction, experiment planning, and laboratory automation. Organizations are placing greater emphasis on human-in-the-loop validation, explainability, reproducibility, and the ability to trace model outputs to source data and experimental evidence. Standardized data practices, cloud and high-performance computing access, and integration with laboratory information systems are becoming central to operational effectiveness. At the same time, model performance remains sensitive to dataset bias, incomplete annotations, distribution shifts, and limited representation of novel chemical and biological spaces.

Artificial Intelligence Expands Prioritization While Preserving Scientific Oversight

Artificial intelligence can help researchers rank targets, identify molecular patterns, propose candidate compounds, predict selected properties, and reduce repetitive analysis. Generative approaches may broaden the range of candidates considered, while multimodal systems can connect chemical, genomic, structural, phenotypic, and clinical information. These benefits do not eliminate the need for experimental confirmation: prediction uncertainty, assay variability, off-target effects, toxicity, manufacturability, and clinical relevance must still be evaluated. Effective deployment therefore combines model monitoring, independent validation, version control, secure data governance, and clear accountability for decisions influenced by algorithmic outputs.

Regional Adoption Reflects Research Capacity, Data Policy, and Infrastructure

North America combines substantial pharmaceutical and biotechnology activity with advanced computing, venture ecosystems, and established translational research networks, while data governance and regulatory expectations shape implementation. Europe benefits from strong academic science, cross-border collaboration, and coordinated research programs; privacy, interoperability, and compliance requirements are particularly influential. Asia-Pacific is supported by expanding biomedical research, pharmaceutical manufacturing capabilities, and investment in digital infrastructure, although capability varies across markets. Latin America is developing applications through universities, public research institutions, and biotechnology initiatives, with access to specialized computing, high-quality datasets, and funding remaining important constraints. The Middle East is building research and innovation capacity through national technology programs and institutional investment. Africa shows growing interest in digital health and computational biology, while connectivity, data availability, local expertise, and sustainable financing remain central adoption considerations.

Multilateral Groups Shape Standards, Funding, and Collaboration

ASEAN cooperation can support shared research infrastructure, interoperable data practices, and cross-border skills development despite differences in national capacity. BRICS members bring significant scientific, industrial, and population-scale data resources, while collaboration is influenced by differing governance frameworks and research priorities. The European Union emphasizes coordinated research, privacy protection, trustworthy artificial intelligence, and cross-border data exchange. G7 economies contribute advanced life-science ecosystems and policy discussions concerning responsible AI, security, and research integrity. GCC countries are investing in digital transformation, specialized research capabilities, and knowledge-intensive sectors, with talent development and international partnerships remaining important. NATO members have strong scientific and technology networks, while cybersecurity, resilience, and protection of sensitive biomedical information are relevant to software deployment.

Country-Level Conditions Create Distinct Deployment Priorities

Australia combines strong biomedical research with geographically distributed institutions, making cloud access, collaboration, and data governance important. Brazil has a broad research base and substantial biological diversity, while infrastructure and data standardization can affect implementation. Canada benefits from established life-science and artificial-intelligence research communities, with privacy, interoperability, and talent mobility shaping projects. China is advancing computational biology, pharmaceutical innovation, and domestic technology capabilities within a distinctive regulatory and data environment. France and Germany pair strong academic and industrial research with European compliance requirements; France emphasizes coordinated innovation, while Germany places notable weight on engineering rigor and industrial integration. India offers expanding software expertise, pharmaceutical capabilities, and a large scientific workforce, with quality-controlled data and specialized training supporting adoption. Italy and Spain have active academic and biotechnology communities, where collaboration and access to advanced infrastructure remain significant. Japan combines sophisticated pharmaceutical research, robotics, and precision engineering, while South Korea links strong technology capabilities with biotechnology and manufacturing. Mexico is developing computational and biotechnology capacity through academic and industrial networks. Russia retains scientific and mathematical expertise, although access to international collaboration, infrastructure, and data can influence deployment. The United Kingdom has a strong life-science and research environment with emphasis on translational applications, governance, and partnerships. The United States combines extensive biomedical research, technology, and investment ecosystems, while regulatory scrutiny, data protection, and integration across organizations remain key considerations.

Leaders Should Build Governed, Interoperable, and Experiment-Linked AI Programs

Industry leaders should begin with well-defined scientific use cases tied to measurable workflow improvements rather than deploying general-purpose tools without validation. They should establish controlled data foundations covering provenance, consent, quality, access rights, labeling, and documentation, then connect software with existing laboratory, analytics, and knowledge-management systems. Model selection should include benchmarking against relevant baselines, uncertainty assessment, bias testing, auditability, and prospective experimental validation. Organizations should create cross-functional governance involving discovery scientists, data specialists, software engineers, quality professionals, legal teams, and cybersecurity experts. Workforce programs should combine computational and laboratory expertise, while procurement and partnership decisions should address portability, intellectual property, service continuity, security, and regulatory support.

Methodology: Evidence-Based Assessment of Technology, Workflow, and Geography

This executive summary uses a structured qualitative assessment of AI-assisted drug discovery software across scientific workflows, enabling technologies, organizational requirements, governance considerations, and geographic ecosystems. The analysis distinguishes software capabilities from confirmed scientific outcomes and avoids treating model claims as evidence without validation. Regional, group, and country perspectives consider research infrastructure, pharmaceutical and biotechnology activity, digital readiness, data-policy environments, skills, collaboration patterns, and barriers to implementation. Conclusions are framed around observable adoption conditions and operational implications rather than market estimates, market sizing, market shares, or forecasts. Because capabilities and regulations evolve, organizations should validate current conditions against primary scientific, regulatory, institutional, and technical sources before making investment decisions.

Responsible Integration Will Determine the Value of AI in Drug Discovery

AI-assisted software is becoming an important layer in modern drug discovery, but its contribution depends on the quality of underlying evidence and the discipline of surrounding workflows. The strongest programs integrate computational recommendations with expert judgment, rigorous experiments, transparent governance, and secure, interoperable data systems. Regional and national differences will influence how quickly capabilities are adopted, while collaboration across research, industry, government, and technology communities can help address skills and infrastructure gaps. Leaders that prioritize scientific validation, reproducibility, responsible use, and practical laboratory integration will be better positioned to convert artificial intelligence into dependable discovery support.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. AI-Assisted Drug Discovery Software Market, by Technique
7.1. Introduction
7.2. Deep Learning
7.2.1. Autoencoders
7.2.2. Convolutional Neural Networks
7.2.3. Recurrent Neural Networks
7.3. Ligand Based
7.4. Machine Learning
7.4.1. Reinforcement Learning
7.4.2. Supervised Learning
7.4.3. Unsupervised Learning
7.5. Structure Based
8. AI-Assisted Drug Discovery Software Market, by Deployment Model
8.1. Introduction
8.2. Cloud
8.3. Hybrid
8.4. On Premises
9. AI-Assisted Drug Discovery Software Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiovascular
9.3. Central Nervous System
9.4. Infectious Diseases
9.5. Oncology
10. AI-Assisted Drug Discovery Software Market, by Application
10.1. Introduction
10.2. Clinical Trial Design
10.3. Lead Optimization
10.4. Pharmacovigilance
10.5. Target Identification
11. AI-Assisted Drug Discovery Software Market, by End User
11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
12. AI-Assisted Drug Discovery Software Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. AI-Assisted Drug Discovery Software Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. AI-Assisted Drug Discovery Software Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aitia Inc.
16.2. Ardigen Sp. z o.o.
16.3. Atomwise Inc.
16.4. BenevolentAI Limited
16.5. Berg LLC
16.6. BioSymetrics, Inc.
16.7. BioXcel Therapeutics, Inc.
16.8. Cloud Pharmaceuticals, Inc.
16.9. Cresset Group Ltd.
16.10. Cyclica Inc.
16.11. Deep Genomics Inc.
16.12. Eagle Genomics Ltd.
16.13. Exscientia PLC
16.14. GNS Healthcare Inc.
16.15. Iktos SAS
16.16. Insilico Medicine, Inc.
16.17. Isomorphic Labs Ltd.
16.18. NVIDIA Corporation
16.19. Owkin SAS
16.20. Peptilogics, Inc.
16.21. Recursion Pharmaceuticals, Inc.
16.22. Schrödinger, Inc.
16.23. Valo Health, Inc.
16.24. Verge Genomics, Inc.
16.25. XtalPi Holdings Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global AI-Assisted Drug Discovery Software Market, Years Considered for the Study
FIGURE 2. Global AI-Assisted Drug Discovery Software Market, Research Design
FIGURE 3. Global AI-Assisted Drug Discovery Software Market, Research Framework
FIGURE 4. Global AI-Assisted Drug Discovery Software Market, Data Triangulation
FIGURE 5. Global AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
FIGURE 6. Global AI-Assisted Drug Discovery Software Market Size, by Technique, 2025 vs 2032 (%)
FIGURE 7. Global AI-Assisted Drug Discovery Software Market Size, by Technique, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2025 vs 2032 (%)
FIGURE 9. Global AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 11. Global AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global AI-Assisted Drug Discovery Software Market Size, by Application, 2025 vs 2032 (%)
FIGURE 13. Global AI-Assisted Drug Discovery Software Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global AI-Assisted Drug Discovery Software Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global AI-Assisted Drug Discovery Software Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global AI-Assisted Drug Discovery Software Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global AI-Assisted Drug Discovery Software Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global AI-Assisted Drug Discovery Software Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global AI-Assisted Drug Discovery Software Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global AI-Assisted Drug Discovery Software Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global AI-Assisted Drug Discovery Software Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global AI-Assisted Drug Discovery Software Market Segmentation & Coverage
TABLE 2. Global AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 3. Global AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 4. Global Deep Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Deep Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Deep Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Autoencoders Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Autoencoders Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Autoencoders Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Convolutional Neural Networks Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Convolutional Neural Networks Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Convolutional Neural Networks Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Recurrent Neural Networks Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Recurrent Neural Networks Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Recurrent Neural Networks Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Ligand Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Ligand Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Ligand Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Machine Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Machine Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Machine Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Reinforcement Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Reinforcement Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Reinforcement Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Supervised Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Supervised Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Supervised Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Unsupervised Learning Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Unsupervised Learning Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Unsupervised Learning Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Structure Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Structure Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Structure Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 35. Global Cloud Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Cloud Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Cloud Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Hybrid Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hybrid Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hybrid Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global On Premises Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global On Premises Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global On Premises Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 45. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. Global Clinical Trial Design Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Clinical Trial Design Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Clinical Trial Design Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Lead Optimization Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Lead Optimization Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Lead Optimization Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Pharmacovigilance Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Pharmacovigilance Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Pharmacovigilance Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Target Identification Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Target Identification Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Target Identification Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. North America AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. North America AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 91. North America AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 92. North America AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 93. North America AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 94. North America AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 95. North America AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. North America AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Latin America AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Latin America AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 99. Latin America AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 100. Latin America AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 101. Latin America AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 102. Latin America AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 103. Latin America AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 104. Latin America AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Europe AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Europe AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 107. Europe AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 108. Europe AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 109. Europe AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 110. Europe AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 111. Europe AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 112. Europe AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Middle East AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Middle East AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 115. Middle East AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 116. Middle East AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 117. Middle East AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 118. Middle East AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 119. Middle East AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 120. Middle East AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. Africa AI-Assisted Drug Discovery Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Africa AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 123. Africa AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 124. Africa AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 125. Africa AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 126. Africa AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 127. Africa AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 128. Africa AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Global AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. ASEAN AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. ASEAN AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 132. ASEAN AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 133. ASEAN AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 134. ASEAN AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 135. ASEAN AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 136. ASEAN AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 137. ASEAN AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. GCC AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. GCC AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 140. GCC AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 141. GCC AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 142. GCC AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 143. GCC AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 144. GCC AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 145. GCC AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. European Union AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. European Union AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 148. European Union AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 149. European Union AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 150. European Union AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 151. European Union AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 152. European Union AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 153. European Union AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. BRICS AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. BRICS AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 156. BRICS AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 157. BRICS AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 158. BRICS AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 159. BRICS AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 160. BRICS AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. BRICS AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. G7 AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. G7 AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 164. G7 AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 165. G7 AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 166. G7 AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 167. G7 AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 168. G7 AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. G7 AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. NATO AI-Assisted Drug Discovery Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. NATO AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 172. NATO AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 173. NATO AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 174. NATO AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 175. NATO AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 176. NATO AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 177. NATO AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Global AI-Assisted Drug Discovery Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. United States AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 180. United States AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 181. United States AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 182. United States AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 183. United States AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 184. United States AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 185. United States AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. United States AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Canada AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 188. Canada AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 189. Canada AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 190. Canada AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 191. Canada AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 192. Canada AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 193. Canada AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. Canada AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Mexico AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 196. Mexico AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 197. Mexico AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 198. Mexico AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 199. Mexico AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 200. Mexico AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 201. Mexico AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 202. Mexico AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Brazil AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 204. Brazil AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 205. Brazil AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 206. Brazil AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 207. Brazil AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 208. Brazil AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 209. Brazil AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. Brazil AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. United Kingdom AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 212. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 213. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 214. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 215. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 216. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 217. United Kingdom AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 218. United Kingdom AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Germany AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 220. Germany AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 221. Germany AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 222. Germany AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 223. Germany AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 224. Germany AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 225. Germany AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 226. Germany AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. France AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 228. France AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 229. France AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 230. France AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 231. France AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 232. France AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 233. France AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 234. France AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Russia AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 236. Russia AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 237. Russia AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 238. Russia AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 239. Russia AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 240. Russia AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 241. Russia AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 242. Russia AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Italy AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 244. Italy AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 245. Italy AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 246. Italy AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 247. Italy AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 248. Italy AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 249. Italy AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. Italy AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. Spain AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 252. Spain AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 253. Spain AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 254. Spain AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 255. Spain AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 256. Spain AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 257. Spain AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 258. Spain AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. China AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 260. China AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 261. China AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 262. China AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 263. China AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 264. China AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 265. China AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 266. China AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. India AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 268. India AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 269. India AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 270. India AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 271. India AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 272. India AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 273. India AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 274. India AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Japan AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 276. Japan AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 277. Japan AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 278. Japan AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 279. Japan AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 280. Japan AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 281. Japan AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 282. Japan AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Australia AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 284. Australia AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 285. Australia AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 286. Australia AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 287. Australia AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 288. Australia AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 289. Australia AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 290. Australia AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. South Korea AI-Assisted Drug Discovery Software Market Size, 2017-2032 (USD Million)
TABLE 292. South Korea AI-Assisted Drug Discovery Software Market Size, by Technique, 2017-2032 (USD Million)
TABLE 293. South Korea AI-Assisted Drug Discovery Software Market Size, by Deep Learning, 2017-2032 (USD Million)
TABLE 294. South Korea AI-Assisted Drug Discovery Software Market Size, by Machine Learning, 2017-2032 (USD Million)
TABLE 295. South Korea AI-Assisted Drug Discovery Software Market Size, by Deployment Model, 2017-2032 (USD Million)
TABLE 296. South Korea AI-Assisted Drug Discovery Software Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 297. South Korea AI-Assisted Drug Discovery Software Market Size, by Application, 2017-2032 (USD Million)
TABLE 298. South Korea AI-Assisted Drug Discovery Software Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. Global AI-Assisted Drug Discovery Software Market Share, by Key Player, 2025
TABLE 300. Global AI-Assisted Drug Discovery Software Market, Key Experts

Companies Mentioned

  • Aitia Inc.
  • Ardigen Sp. z o.o.
  • Atomwise Inc.
  • BenevolentAI Limited
  • Berg LLC
  • BioSymetrics, Inc.
  • BioXcel Therapeutics, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cresset Group Ltd.
  • Cyclica Inc.
  • Deep Genomics Inc.
  • Eagle Genomics Ltd.
  • Exscientia PLC
  • GNS Healthcare Inc.
  • Iktos SAS
  • Insilico Medicine, Inc.
  • Isomorphic Labs Ltd.
  • NVIDIA Corporation
  • Owkin SAS
  • Peptilogics, Inc.
  • Recursion Pharmaceuticals, Inc.
  • Schrödinger, Inc.
  • Valo Health, Inc.
  • Verge Genomics, Inc.
  • XtalPi Holdings Limited

Related Topics

Related Reports

AI in Drug Discovery - Global Strategic Business Report - Product Image

AI in Drug Discovery - Global Strategic Business Report

  • Report
  • 493 Pages
  • Global
From
AI in Drug Discovery Market Report 2026 - Product Image

AI in Drug Discovery Market Report 2026

  • Report
  • 250 Pages
  • Global
From
AI in Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

AI in Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
AI in Drug Discovery Market (3rd Edition) by Drug Discovery Step, Type of AI Technology, Therapeutic Area, End User and Geographical Regions - Trends and Forecast, Till 2035 - Product Image

AI in Drug Discovery Market (3rd Edition) by Drug Discovery Step, Type of AI Technology, Therapeutic Area, End User and Geographical Regions - Trends and Forecast, Till 2035

  • Report
  • 365 Pages
  • Global
From
AI for Drug Discovery Market Insights, Competitive Landscape, and Market Forecast - 2033 - Product Image

AI for Drug Discovery Market Insights, Competitive Landscape, and Market Forecast - 2033

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.